Dél-pesti Centrumkórház–Országos Hematológiai és Infektológiai Intézet, Onkológia Osztály, Budapest
The past two decades have seen many landmark changes in the treatment of metastatic prostate cancer. With the introduction of new generation hormone preparations, in addition to standard chemotherapy, new therapeutic routes have opened up, making it possible to offer patients effective treatment options even before chemotherapy. In addition to the widespread use of these endocrine therapies, precision medicine is also playing an increasingly important role in this patient group. In the metastatic stage, determining the BRCA mutation is now essential for planning sequential therapy. In addition to the ever-expanding medical treatment options, research with various radioisotope treatments is experiencing a renaissance. This publication aims to provide an overview of the currently used therapies and to present the results of the latest clinical trials to guide the practicing clinician in setting up an individualized treatment sequence.